BCLAF1 and colorectal carcinoma: In a study of colon cancer, researchers found that another option to inhibit ASCL2 expression was promoter methylation mediated by TET2-BCLAF1.[21] Another study on colon cancer suggested that the dynamics of activated enhancers inhibit CRC progression and that patient-specific enhancer patterns are affected by precision therapy.[22] Other colon cancer studies have suggested a link between the dysregulation of ASCL2 and MSS in CRC.[23]